INNOVATIVE NASAL VACCINES TO PREVENT PATHOGEN COLONIZATION AND INFECTION IN THE UPPER RESPIRATORY TRACT

Project Information

NOSEVAC

Grant agreement ID: 101080528

DOI

10.3030/101080528

EC signature date 21 April 2023

Start date 1 May 2023

End date 30 April 2028

Funded under

• Health

Total cost

€ 7 369 448,75

EU contribution

€ 7 369 448,75

Coordinated by

EUROPEAN VACCINE INITIATIVE EV
Germany

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Publications

Peer reviewed articles (3)

Steps towards licensure of self-amplifying RNA vaccines

Author(s): Maarten F Wilbrink, Sander Herfst, Rory D de Vries
Published in: The Lancet Infectious Diseases, 2024, ISSN 1473-3099
Publisher: Elsevier BV
DOI: 10.1016/S1473-3099(24)00593-0

Studying Early Life Live-Attenuated influenza virus immune Responses (STELLAR): study protocol for an exploratory observational study of the nasal mucosal and systemic immune response in healthy children given an intranasal live-attenuated influenza vaccine

Author(s): Karen Kelleher, Reuben Bennett, Rebecca Jackson, Lauri Ivaska, Nisha Singh, Reyna Sara Quintero Barceinas, Emma Plested, Emma Francis, Yama F Mujadidi, Chidimma Nwankwo, Jack Francis-Hill, Amber Thompson, Carla Solórzano, Hannah Baughan, Xinxue Liu, Arnaud M Didierlaurent, Britta C Urban, Daniela M Ferreira, Dominic Kelly
Published in: BMJ Open, Issue 16, 2026, ISSN 2044-6055
Publisher: BMJ
DOI: 10.1136/BMJOPEN-2025-114107

Self-amplifying RNA vaccines against antigenically distinct SARS-CoV-2 variants

Author(s): Sander Herfst, Rory D de Vries
Published in: The Lancet Infectious Diseases, Issue 24, 2024, ISSN 1473-3099
Publisher: Elsevier BV
DOI: 10.1016/S1473-3099(23)00734-X